BayMark Health Services announced the acquisition of Metamorphosis, an Opioid Treatment Program (OTP) with locations in Salt Lake City and Ogden, Utah earlier this week. Providing medication-assisted treatment since 1995, Metamorphosis has established themselves as a high-quality, trusted provider of evidence-based treatment for opioid addiction. The Metamorphosis programs will become BAART Programs Salt Lake City and BAART Programs Ogden.
“Metamorphosis was founded in 1995 to provide much needed services to the greater Salt Lake City area where there wasn’t a large number of options for those seeking medication-assisted treatment for opioid addiction,” stated Shannon Terwedo, President of Metamorphosis. “We have worked over the last 20 years to create safe and effective recovery programs for our patients and to educate our community about the benefits of this proven treatment modality. We feel confident that BayMark will continue our mission and maintain the highest levels of care for our patients.”
BAART Programs, a BayMark Health Services company, provides outpatient medication-assisted treatment (MAT) for opioid addiction and dependency. Medication-assisted treatment combines medications, such as methadone and buprenorphine, with addiction counseling and behavioral therapies. This approach provides an evidence-based, comprehensive treatment plan, individualized to meet the needs of each patient.
David K. White, Ph.D., Chief Executive Officer of BayMark Health Services, added, “As the opioid epidemic persists, accessibility to proven treatment options for opioid addiction is critical. BayMark has over 50 years of cumulative experience in treating this disease and looks to work with organizations who have established a foundation of quality care and compassion in their practices. Our goal is to build upon the great services offered by Metamorphosis by bringing new and fresh ideas. We look forward to continuing and adding to the legacy established by Metamorphosis!”
This article originally appeared in an article on PRWeb.